News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Subscribe To Our Newsletter & Stay Updated
